3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
6
Phase NA
3
Phase 2
2
Phase 1/2
2
Status
Completed
2
Withdrawn
1
Unknown
1
Recruiting
1
Not yet recruiting
1
Sponsor Class
UNKNOWN
1
OTHER
1
Study Type
Interventional
2
Sponsor
Conditions
Pain
2
Parasomnias
1
Neoplasms
1
Nausea
1
Anxiety Disorders
1
Interventions
Cyclophosphamide
741
Cisplatin
688
Gemcitabine
641
Bevacizumab
616
Carboplatin
605
Paclitaxel
601
Docetaxel
565
Radiotherapy
536
Fluorouracil
405
Oxaliplatin
387
Rituximab
369
Doxorubicin
361
Capecitabine
342
Filgrastim
333
Etoposide
330
Dexamethasone
312
Irinotecan
309
pembrolizumab
282
Leucovorin
274
Cetuximab
268
Cytarabine
242
Erlotinib Hydrochloride
231
Nivolumab
228
Prednisone
227
Trastuzumab
225
Vincristine
221
Bortezomib
221
Methotrexate
207
Pemetrexed
199
fludarabine phosphate
195
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Completed
×
nabiximols
×
Clear all
NCT03948074
2025-09-10
CAFCARS
British Columbia Cancer Agency
Phase 2
Completed
91 enrolled
NCT00530764
2013-06-20
SPRAY
GWPharm
Phase 2
Completed
360 enrolled
18 charts